Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)
JN Bodor, Y Boumber, H Borghaei - Cancer, 2020 - Wiley Online Library
The emergence of immunotherapy has dramatically changed how non–small cell lung
cancer is treated, and longer survival is now possible for some patients, even those with
advanced disease. Although some patients achieve durable responses to checkpoint
blockade, not all experience such benefits, and some suffer from significant
immunotoxicities. Given this, biomarkers that predict response to therapy are essential, and
testing for tumor programmed death ligand 1 (PD‐L1) expression is the current standard …
cancer is treated, and longer survival is now possible for some patients, even those with
advanced disease. Although some patients achieve durable responses to checkpoint
blockade, not all experience such benefits, and some suffer from significant
immunotoxicities. Given this, biomarkers that predict response to therapy are essential, and
testing for tumor programmed death ligand 1 (PD‐L1) expression is the current standard …
Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)
H Borghaei, J Bodor, Y Boumber - dspace.kpfu.ru
© 2019 American Cancer Society The emergence of immunotherapy has dramatically
changed how non–small-cell lung cancer is treated, and longer survival is now possible for
some patients, even those with advanced disease. Although some patients achieve durable
responses to checkpoint blockade, not all experience such benefits, and some suffer from
significant immunotoxicities. Given this, biomarkers that predict response to therapy are
essential, and testing for tumor programmed death ligand 1 (PD-L1) expression is the …
changed how non–small-cell lung cancer is treated, and longer survival is now possible for
some patients, even those with advanced disease. Although some patients achieve durable
responses to checkpoint blockade, not all experience such benefits, and some suffer from
significant immunotoxicities. Given this, biomarkers that predict response to therapy are
essential, and testing for tumor programmed death ligand 1 (PD-L1) expression is the …
以上显示的是最相近的搜索结果。 查看全部搜索结果